In an older trial, which included patients with completely resected stage IV or high-risk stage III melanoma, adjuvant granulocyte-macrophage colony stimulating factor (GM-CSF) did not demonstrate improvements in RFS or OS in a randomized, placebo-controlled phase 3 study [35]. Here, CSF2 is linked to melanoma.